Do we need to consider inflammatory markers when we treat atherosclerotic disease?

Atherosclerosis
Vasilios G AthyrosDimitri P Mikhailidis

Abstract

This review considers the value of monitoring inflammatory markers as a guide to selecting appropriate drugs in patients at high risk of cardiovascular disease (CVD). Clinical and experimental studies investigated inflammation in patients with acute coronary syndromes (ACS), stable coronary artery disease (CAD) and diabetes mellitus (DM) or metabolic syndrome (MetS), non-alcoholic fatty liver disease (NAFLD) or systemic autoimmune diseases (SAD). Evidence suggests that in these high risk groups inflammation plays a role in the extent and severity of atherosclerosis. Simple inflammatory markers (e.g. C-reactive protein and fibrinogen) can be monitored cost effectively and may influence the selection of drugs that can normalize both traditional CVD risk factors and inflammation. However, this concept requires proof in appropriately designed trials that include clinically relevant end points.

References

Nov 24, 1999·The American Journal of Medicine·G MarchesiniN Melchionda
Nov 26, 1999·Circulation·V Pasceri, E T Yeh
Jun 1, 2001·Regulatory Peptides·M Stoll, T Unger
Feb 2, 2002·Current Atherosclerosis Reports·John A Farmer, Guillermo Torre-Amione
Jun 19, 2002·Trends in Cardiovascular Medicine·Burkhard LudewigHans Hengartner
Oct 10, 2002·American Journal of Nephrology·Noako YokotaHamid Rabb
Nov 28, 2002·Journal of Gastroenterology and Hepatology·Brian P MulhallZobair M Younossi
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Dec 20, 2002·Nature·Peter Libby
Mar 12, 2003·Circulation·Daniel H SolomonGary C Curhan
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
May 16, 2003·Nature·Gary S Firestein
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Oct 2, 2003·Vascular Medicine·Peter Leong-Sit, Sonia S Anand
Dec 12, 2003·Angiology·Vasilios G AthyrosUNKNOWN GREACE Study Collaborative Group
Feb 7, 2004·The Journal of Clinical Endocrinology and Metabolism·Panayiotis A EconomidesAristidis Veves
Mar 30, 2004·Diabetes Care·Matthias B SchulzeFrank B Hu
Sep 1, 2004·JAMA : the Journal of the American Medical Association·Steven E Nissen
Sep 1, 2004·JAMA : the Journal of the American Medical Association·James A de LemosUNKNOWN Investigators
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Sep 24, 2004·The New England Journal of Medicine·Nagesh S AnavekarMarc A Pfeffer
Oct 12, 2004·Journal of Cardiovascular Pharmacology·Monika GraningerBernd Jilma
Nov 16, 2004·Journal of the American College of Cardiology·Doron AronsonGerald J Brook
Dec 14, 2004·Current Medical Research and Opinion·Vasilios G AthyrosUNKNOWN METS-GREECE Collaborative Group
Jun 25, 2005·Journal of the American Society of Nephrology : JASN·Raymond Harris
Aug 11, 2005·Metabolism: Clinical and Experimental·Vasilios G AthyrosMoses Elisaf
Aug 30, 2005·The American Journal of Cardiology·Gregg C FonarowUNKNOWN National Registry of Myocardial Infarction 4 Investigators
Oct 18, 2005·Trends in Cardiovascular Medicine·Ravichandran RamasamyAnn Marie Schmidt

❮ Previous
Next ❯

Citations

Dec 12, 2012·Amino Acids·Elisabetta GianazzaMaurizio Crestani
Nov 26, 2009·The Journal of Cardiovascular Nursing·Theresa M BeckieMaureen W Groer
Jan 8, 2009·International Journal of Clinical Practice·V G AthyrosD P Mikhailidis
Jan 1, 2009·Journal of Ophthalmology·Paul P ConnellStephen Beatty
Oct 11, 2012·Revista brasileira de hematologia e hemoterapia·Luciana Moreira LimaMarinez de Oliveira Sousa
May 7, 2009·Current Opinion in Cardiology·Konstantinos TziomalosDimitri P Mikhailidis
Feb 20, 2016·Journal of Clinical Lipidology·Harold E BaysTerry A Jacobson
Jul 31, 2013·Expert Opinion on Investigational Drugs·Vasilios G AthyrosDimitri P Mikhailidis
Jun 14, 2008·Expert Opinion on Investigational Drugs·Vasilios G AthyrosDimitri P Mikhailidis
Sep 17, 2010·Current Medical Research and Opinion·Maria SarigianniDimitri P Mikhailidis
Feb 6, 2010·Current Medical Research and Opinion·Vasilios G AthyrosDimitri P Mikhailidis
Feb 13, 2009·Current Medical Research and Opinion·Konstantinos TziomalosDimitri P Mikhailidis
Oct 17, 2013·Current Medical Research and Opinion·Vasilios G AthyrosDimitri P Mikhailidis
Feb 26, 2013·Journal of Proteomics·Ivano EberiniElisabetta Gianazza
Sep 21, 2010·Clinica Chimica Acta; International Journal of Clinical Chemistry·Nikolaos P E KadoglouStilianos Lampropoulos
Feb 23, 2010·Primary Care Diabetes·Niina MatikainenMarja-Riitta Taskinen
Nov 13, 2009·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Rossella Di StefanoAlberto Balbarini
Jul 15, 2009·The Journal of Pediatrics·Idoia LabayenJonatan R Ruiz
Nov 3, 2009·Evidence-based Complementary and Alternative Medicine : ECAM·Sung-Hui TsengChing-Chiung Wang
Feb 26, 2011·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·V G AthyrosD P Mikhailidis
Jul 17, 2014·Seizure : the Journal of the British Epilepsy Association·Niki KatsikiDevaki R Nair
Dec 20, 2014·Journal of Clinical Lipidology·Harold E BaysTerry A Jacobson
Jul 24, 2014·Angiology·Andreja TrpkovicEsma R Isenovic
Mar 13, 2013·Angiology·Sevket BaltaHamidullah Haqmal
Mar 20, 2013·Angiology·Vasilios G AthyrosAsterios Karagiannis
Feb 6, 2015·Angiology·Sevket BaltaAtila Iyisoy
Dec 8, 2010·Angiology·Kosmas I ParaskevasDimitri P Mikhailidis
Jun 22, 2017·Journal of Cellular Biochemistry·Wen-Han GeZhong-Chun Ge
Oct 23, 2018·Angiology·Despina D Briana, Ariadne Malamitsi-Puchner
May 23, 2018·The Open Cardiovascular Medicine Journal·Andromachi ReklouVasilios G Athyros
Dec 31, 2011·The Open Cardiovascular Medicine Journal·Vasilios G AthyrosAsterios Karagiannis
Jul 3, 2009·The Open Cardiovascular Medicine Journal·Konstantinos TziomalosDimitri P Mikhailidis
Oct 24, 2019·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Federico PaceiRaffaele Nardone
Jan 1, 2008·The Open Cardiovascular Medicine Journal·Michael KoutouzisZenon S Kyriakides
Mar 9, 2013·Angiology·Sevket BaltaMehmet Yokusoglu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cell Adhesion Molecules in AS

Cell adhesion molecules expressed on the vascular endothelium and circulating leukocytes in response to inflammatory stimuli are implicated in atherosclerosis. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.